Press release
Oral Solid Dosage Pharmaceutical Formulation: Critical Driver Shaping the Chronic Disease Prevalence Drive Growth In The Oral Solid Dosage Pharmaceutical Formulation Market Market in 2025
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.Oral Solid Dosage Pharmaceutical Formulation Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for oral solid dosage pharmaceutical formulations has seen robust growth in the last few years. Its size is expected to increase from $618.34 billion in 2024 to $653.26 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. Factors contributing to the growth during the historical period include the prevalence of chronic diseases, an aging population, expanded access to healthcare, promotion of generic formulations, and a shift in consumer preference.
Oral Solid Dosage Pharmaceutical Formulation Market Size Forecast: What's the Projected Valuation by 2029?
The market for oral solid dosage pharmaceutical formulations is anticipated to witness notable expansion in the coming years, forecasted to reach a substantial $810.94 billion by 2029, escalating at a Compound Annual Growth Rate (CAGR) of 5.6%. This growth trajectory during the projected period can be attributed to the rising demand for personalized medicine, increased adoption of controlled-release methods, the concentrated focus on biopharmaceuticals, expansion in emerging markets, and changes in policy and reimbursement dynamics. Key trends expected during this forecast period also include increased integration of digital health, the expansion of telemedicine services, preventative healthcare focus, and the ongoing inclusion of artificial intelligence within the healthcare sector.
View the full report here:
https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report
What Are the Drivers Transforming the Oral Solid Dosage Pharmaceutical Formulation Market?
The surge in chronic illnesses is projected to spur the expansion of the oral solid dosage pharmaceutical formulation market. Chronic illnesses constitute long-term medical conditions that last for numerous months, generally more than three. The rise in chronic diseases is attributed to aspects such as the aging populace, inactive lifestyles, unhealthy eating habits, environmental elements, and enhanced detection and diagnostic techniques. Oral solid dosage pharmaceutical formulations are crucial for managing chronic diseases and fostering long-term treatment adherence due to their convenience, stability, and accurate dosing. For example, the World Health Organization, an intergovernmental organization based in Switzerland, forecasted in February 2024 that more than 35 million new cancer cases would surface by 2050, denoting a 77% rise compared to the projected 20 million cases in 2022. Consequently, the escalating prevalence of chronic diseases fuels the growth of the oral solid dosage pharmaceutical formulation market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15626&type=smp
What Are the Key Trends Driving Oral Solid Dosage Pharmaceutical Formulation Market Growth?
Top firms in the market for oral solid dosage pharmaceutical formulation are pioneering cutting-edge products like liquid-filled capsules to bolster drug delivery, increase bioavailability, and present more patient-friendly dosing alternatives. Liquid-filled capsules are forms of oral dosage, featuring a gelatin shell that contains a liquid or semi-solid formulation with active pharmaceutical ingredients (APIs) and excipients. For instance, in July 2023, Zeon Lifesciences Ltd., a pharmaceutical company based out of India, debuted its liquid-filled capsules, supplying a groundbreaking drug delivery system with superior bioavailability and absorption rates. These capsules use a groundbreaking delivery method that amplifies bioavailability and absorption rates, guaranteeing an ideal amount of active ingredients for ultimate effectiveness and swift outcomes. Zeon's liquid-filled capsules allow for precise and uniform dosages, enhancing patient adherence and command over drug administration. They make use of state of the art technologies to boost bioavailability, elevate patient results, and safeguard the medication's quality. Zeon's liquid-filled capsules furnish a practical, potent, and dependable substitute to conventional dosage forms, thereby establishing a novel benchmark in patient care and adherence within the pharmaceutical sector.
Which Segments in the Oral Solid Dosage Pharmaceutical Formulation Market Offer the Most Profit Potential?
The oral solid dosage pharmaceutical formulation market covered in this report is segmented -
1) By Dosage Form: Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gum*mies
2) By Mechanism: Controlled-Release, Immediate-Release, Delayed-Release
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets Or Supermarkets
4) By End-User: Large-Size Companies, Medium And Small-Size Companies, Other End-Users
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Controlled-Release Tablets, Effervescent Tablets, Chewable Tablets, Sublingual Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Liquid-Filled Capsules, Delayed-Release Capsules
3) By Powders And Granules: Oral Powders (Reconstitution), Granules (Oral Suspension Or Dispersible Granules)
4) By Lozenges And Pastilles: Medicinal Lozenges, Herbal Lozenges, Sugar-Free Lozenges, Pastilles ( Throat Or Cough Relief)
5) By Gum*mies: Vitamin Gum*mies, Herbal And Nutritional Supplement Gum*mies, Pharmaceutical Gum*mies ( Pain Relief Or Sleep Aids)
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15626&type=smp
Which Firms Dominate the Oral Solid Dosage Pharmaceutical Formulation Market by Market Share and Revenue in 2025?
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International
Which Regions Offer the Highest Growth Potential in the Oral Solid Dosage Pharmaceutical Formulation Market?
North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15626
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oral Solid Dosage Pharmaceutical Formulation: Critical Driver Shaping the Chronic Disease Prevalence Drive Growth In The Oral Solid Dosage Pharmaceutical Formulation Market Market in 2025 here
News-ID: 4182503 • Views: …
More Releases from The Business research company
Zymfentra Market Report Examines Leading Companies And Growth Opportunities
Understanding the Future Outlook of the Zymfentra Market
The Zymfentra market has been evolving steadily, driven by scientific advances and growing healthcare infrastructure. Looking ahead to 2030, the market is expected to witness considerable growth fueled by multiple factors influencing both development and patient care.
Market Size and Growth Drivers for the Zymfentra Market
During the historical period, growth was primarily propelled by improvements in recombinant enzyme technology and better diagnostic…
Zenpep Market Report Provides Insights Into Market Evolution And Growth Prospect …
The Zenpep market is gaining momentum as advancements in digestive health treatments and better disease management continue to evolve. With rising awareness and improved therapies, this sector is positioned for steady growth in the coming years. Let's explore the current market value, key factors driving expansion, leading players, and important segments shaping the future of Zenpep.
Projected Market Value and Growth Drivers for Zenpep by 2030
Historical growth in the Zenpep…
Xyntha,Xyntha Solofuse Market Report Examines Leading Companies And Growth Oppor …
The market for Xyntha and Xyntha Solofuse is poised for significant growth as advancements in hemophilia A treatment continue to evolve. With shifts toward more effective therapies and improved patient management strategies, this industry is set to witness substantial expansion in the coming years. Let's explore the current market value, the key factors driving growth, prominent players, and the main market segments shaping the landscape.
Expected Market Value of the Xyntha…
Xembify Market Report Provides Insights Into Market Evolution And Growth Prospec …
The Xembify market is gaining considerable attention due to advances in treatment options and increased awareness of immune-related disorders. This sector is evolving rapidly, driven by improvements in therapies and expanding patient access. Let's explore the current market size, key growth drivers, prominent players, and emerging trends shaping the future of Xembify.
Market Growth and Prospects for the Xembify Market
The historical expansion of the Xembify market is largely linked to…
More Releases for Pharma
Schizophrenia Market Forecast 2036: Rising Demand, Novel Therapies, and Commerci …
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Otsuka Pharmaceutical, Lyndra Therapeutics, Neurocrine Biosciences, and others.
(Albany, New York) - October 19, 2026: DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis…
Schizophrenia Market Gains Momentum with Expanding Pipeline and Investment Poten …
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Acadia Pharmaceuticals, Boehringer Ingelheim, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed…
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
